CD8A and neoplasm: Recent work showed that PD-1 could be a biomarker for intratumoral, tumor specific CD8+ lymphocytes in melanoma [37] and this could be valid for GBM due to the high percentage of CD8+ cells expressing PD-1 in ours samples, especially in tumors relapse.